Navigation Links
Cell Therapeutics Targeting Potential Zevalin Label Expansion, Pixantrone and OPAXIO Drug Approvals to Grow Commercial Operations and Revenues in 2009
Date:1/14/2009

evalin which doubles the resources available to potentially expand U.S. Zevalin sales following a new first-line consolidation indication.

PIXANTRONE -- Based on preliminary results from its phase III extend trial for Pixantrone reported on November 11, 2008 and a forthcoming FDA meeting later this quarter, CTI currently plans to submit a rolling NDA filing for pixantrone with potential Q4- 2009 approval and launch in U.S. which could result in upfront and approval payment and milestones to CTI should Novartis elect to exercise their option to enter into an exclusive worldwide license to develop and commercialize pixantrone.

OPAXIO -- Potential Marketing Authorization Application approval by the European Medicines Agency or EMEA for OPAXIO for first-line treatment of patients with non-small cell lung cancer (NSCLC). If Novartis elects to commercialize OPAXIO in Europe based on EMEA acceptance of the MAA filing CTI could earn additional cash reimbursement payments and royalties on sales from OPAXIO.

Continued improvement of our capital structure through a comprehensive recapitalization plan intended to help CTI regain compliance with the Nasdaq listing standards, and which may include additional equity or debt offerings, and the reduction of our outstanding indebtedness, through the previously announced potential tender offer for a portion of our outstanding convertible notes or otherwise as disclosed on December 5, 2008.

Review of 2008 Key Accomplishments:

Entered into an agreement with Bayer Schering Pharma to gain access to its positive phase III Zevalin First-line Indolent Trial (FIT) data for submission to the FDA in connection with the Zevalin sBLA.

Successful pre-sBLA meeting with FDA and submission of sBLA for expansion of the label for Zevalin for use in first-line consolidation treatment for non-Hodgkin's lymphoma. FDA has granted the sBLA priority re
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Sept. 19, 2014  Nektar Therapeutics (NASDAQ: ... studies characterizing the analgesic profiles of a series ... receptor agonist molecules. The preclinical research candidates were ... platform. The analgesic properties of kappa ... literature. 1,2 Kappa opioid receptors are expressed ...
(Date:9/19/2014)... September 19, 2014 Barnhardt Manufacturing ... Label for its Organic Cotton . The USDA ... of renewable biobased ingredients meets or exceeds levels set ... composed in whole or in significant part of agricultural, ... allow our Organic cotton to be immediately identified as ...
(Date:9/19/2014)... ROCKLAND, Massachusetts , September 19, 2014 ... with the 53rd European Society for Paediatric Endocrinology (ESPE) ... advancement of science and medical research in the field ... of Merck KGaA, Darmstadt, Germany , ... Growth Innovation (GGI) for 2014. The awards were announced ...
(Date:9/18/2014)... TX (PRWEB) September 18, 2014 ... integrated urological and interventional radiology products and services, ... known as cryotherapy and cryoablation) versus external beam ... Section of the American Urological Association (MAAUA) Annual ... , "Comparing Relative Effectiveness of Cryosurgery and External ...
Breaking Biology Technology:Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 2Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 3Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 4Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 5Barnhardt Manufacturing Company Earns USDA Certified Biobased Product Certification and Label for Organic Cotton 2EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 2EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 3HealthTronics Announces Data Comparing Cryotherapy Versus Radiation for Treating Prostate Cancer Poster Presented at the American Urological Association Regional Meeting 2
... REDWOOD CITY, Calif., Aug. 5 Ingenuity ... life science researchers,today introduced Ingenuity Analysis Services, ... ,omics data related to,compound profiling, target identification, ... are designed to meet the needs of ...
... second quarter stock repurchase program and positive cash flow from ... ... (Nasdaq: AMCS ), a,leader in radiology and medical image and information ... 2008., (Logo: http://www.newscom.com/cgi-bin/prnh/20060202/AMICASLOGO ), Q2 ...
... Quarterly Dacogen Royalty Revenue Increases 76% from Same ... SuperGen, Inc.,(Nasdaq: SUPG ), a pharmaceutical ... of therapies for solid tumors and,hematological malignancies, today ... months ended June 30, 2008., Total revenues ...
Cached Biology Technology:Ingenuity Systems Launches Analysis Services 2AMICAS Reports Financial Results for the Second Quarter Ended June 30, 2008 2AMICAS Reports Financial Results for the Second Quarter Ended June 30, 2008 3AMICAS Reports Financial Results for the Second Quarter Ended June 30, 2008 4AMICAS Reports Financial Results for the Second Quarter Ended June 30, 2008 5AMICAS Reports Financial Results for the Second Quarter Ended June 30, 2008 6AMICAS Reports Financial Results for the Second Quarter Ended June 30, 2008 7AMICAS Reports Financial Results for the Second Quarter Ended June 30, 2008 8AMICAS Reports Financial Results for the Second Quarter Ended June 30, 2008 9AMICAS Reports Financial Results for the Second Quarter Ended June 30, 2008 10AMICAS Reports Financial Results for the Second Quarter Ended June 30, 2008 11AMICAS Reports Financial Results for the Second Quarter Ended June 30, 2008 12SuperGen Reports 2008 Second Quarter Financial Results 2SuperGen Reports 2008 Second Quarter Financial Results 3SuperGen Reports 2008 Second Quarter Financial Results 4SuperGen Reports 2008 Second Quarter Financial Results 5SuperGen Reports 2008 Second Quarter Financial Results 6SuperGen Reports 2008 Second Quarter Financial Results 7SuperGen Reports 2008 Second Quarter Financial Results 8SuperGen Reports 2008 Second Quarter Financial Results 9SuperGen Reports 2008 Second Quarter Financial Results 10SuperGen Reports 2008 Second Quarter Financial Results 11SuperGen Reports 2008 Second Quarter Financial Results 12SuperGen Reports 2008 Second Quarter Financial Results 13
(Date:9/19/2014)... Nxt-ID, Inc. (Nasdaq: NXTD and NXTDW) ... growing m-commerce market, updates the "Wocket in Your Pocket" celebrity ad ... light middleweight weight classes, Vinny Pazienza (PAZ). ... Game of Thrones actor Ciaran Hinds and ... Katey Sagal have been cast in Bleed for ...
(Date:9/18/2014)... A new GSA Bulletin study uses tree ... Puerco and Chaco Wash in northern New Mexico, USA. ... cedar and willow, investigators were able to precisely date ... then combined this data with aerial imagery, LiDAR, longitudinal ... these arroyos. , Arroyos are deep, oversized channels that ...
(Date:9/18/2014)... SAN ANTONIO, September 18, 2014 New research into ... which causes a severe hemorrhagic disease in humans similar ... factors essential for CCHFV infection. This discovery has the ... against the pathogen. , The research, reported ... PLoS Pathogens and conducted by scientists at the ...
Breaking Biology News(10 mins):NXT-ID's Vinny Paz Celebrity Ad Wocket Update: Katey Sagal and Ciaran Hinds Attached to His Upcoming Movie 2NXT-ID's Vinny Paz Celebrity Ad Wocket Update: Katey Sagal and Ciaran Hinds Attached to His Upcoming Movie 3Tree rings and arroyos 2Tree rings and arroyos 3Tree rings and arroyos 4Tree rings and arroyos 5Tree rings and arroyos 6Tree rings and arroyos 7Research milestone in CCHF virus could help identify new treatments 2
... Recent nationwide outbreaks of food-borne illnesses have triggered ... confidence. A symposium at the University of Minnesota ... food-safety issue. The conference, "How Safe is ... take place beginning at 1:30 p.m. Wednesday, April ...
... Commerce Department,s National Institute of Standards and Technology ... process for manufacturing integrated circuits at the nanometer ... to develop a method for engineering the first-ever ... As described in a paper published ...
... RELEASE, 31 March 2009] Researchers at the Swedish medical ... of the brain,s frontal and parietal parts, to increase the ... how the billions of neurons in the brain interact. One ... is a mechanism in the brain,s neuronal network that restricts ...
Cached Biology News:NIST-Cornell team builds world's first nanofluidic device with complex 3-D surfaces 2NIST-Cornell team builds world's first nanofluidic device with complex 3-D surfaces 3NIST-Cornell team builds world's first nanofluidic device with complex 3-D surfaces 4Computer simulations explain the limitations of working memory 2
... scale-up, these culture chambers produce cell yields ... range and are useful alternatives to ... High mechanical • strength and structural integrity ... • Certified nonpyrogenic and sterilized by gamma ...
Mouse monoclonal antibody to QARS - glutaminyl-tRNA synthetase...
... thermostable DNA polymerase obtained by high level ... in E. coli, Concentration: 5U/ul, Applications: Standard ... Scientific, the world leader in serving science. ... the world healthier, cleaner and safer by ...
ABgene® supplies a 94kDa ultra-pure recombinant thermostable DNA polymerase obtained by high level expression of the Taq DNA polymerase gene in E. coli....
Biology Products: